The progression of Duchenne muscular dystrophy

Publisher Website
Google Scholar
Abstract
A 12 mo. clinical study of Duchennne muscular dystrophy was carried out during a double blind trial of allopurinol therapy. The disease was monitored by assessment of muscle power and function, pulmonary function tests and ECG. Biochemical assessments were made of plasma creatine kinase, pyruvate kinase, uric acid and urinary excretion of 3-methylhistidine and creatinine. Allopurinol did not alter the progression of the disease in these patients.

This publication has 0 references indexed in Scilit: